Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35212377

about

Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients Prognostic significance of serum free light chains in chronic lymphocytic leukemia.Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review.Biclonal Gammopathy in Chronic Lymphocytic Leukemia: Case Report and Review of the Literature.Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival.Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma.Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma.Contribution of polyclonal free light chain deposition to tubular injury.Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

P2860

Q35185207-C2BBE894-2B31-48C9-A7B9-9AF671DB984D Q35918672-DCDD1424-81D2-4312-9A62-C1D080C0C656 Q36338377-29D6738E-8C4B-4B9E-8615-BDCA9F71404E Q36592302-9A31E0C1-96B6-4A39-B4DA-4A0A17263E7C Q37316098-6EE3F917-DBD9-4D4C-8A15-1F6A029249D1 Q38010146-14690FBA-8846-4753-9D4C-22805D82EAF0 Q38546557-06025499-E076-4DFF-94F5-7596FFCC2920 Q38924571-DD0D7615-5AFE-44C7-B1B6-24ED3B862A85 Q39140382-C6D99B6A-443A-4D6A-BA41-6A585556ADAF Q39531260-C5A6CDE2-7E6C-4D51-8F92-602A2D74BE38 Q45951051-D7C7906B-F968-40A9-ADE7-8B600D7F01C3 Q50099990-B869170B-DBEA-4263-B974-4A9342A94921 Q51075846-7DCA19B4-E139-427D-962C-DAB1FF828960 Q53117498-34A277B9-C503-453E-AD5C-1E165144E92B Q53147192-2CD79AD7-A6F7-4AA8-9D53-551946E6DBB3

P2860

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35212377

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@ast

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@en

type

label

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@ast

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@en

prefLabel

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@ast

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@en

P1433

Q35212377-F83C4DBF-3843-4B0F-A5D4-006BC9C6A4CA

P1476

Q35212377-90E8EAB7-8716-47B4-962E-0EF1E3C88673

P2093

Q35212377-05390176-A9A4-44D1-A53F-A915A4FA08C3

Q35212377-391F2E11-2709-457C-9088-F95C8B6C2882

Q35212377-62876473-14CA-454E-A94A-95081EA65B6C

Q35212377-6B5D9DC9-099A-45EB-82C3-2E9CAC022805

Q35212377-71345B5B-7753-48A5-9761-C93CA7F26E87

Q35212377-778FC49D-2641-4114-BE9E-79E39A84D4DD

Q35212377-800937E3-CD3B-4BD8-8C5E-1FD1B6739B7D

Q35212377-82C96292-4BC8-4067-8306-5B652B5FAFE4

Q35212377-87AF82D4-1970-4159-AD75-26E101348527

Q35212377-9C03CF2E-6242-4371-BBC7-C3B446DE60F7

P2860

Q35212377-07B1DC1E-3E7B-40DC-B77A-3E082C04606C

Q35212377-0E8678BF-531E-462E-95DB-7CD596BA4A98

Q35212377-3B0302DE-C173-4DA1-96B6-EA9DA5E2563B

Q35212377-3B085058-1FB6-48DA-B4F6-B089CBA7703A

Q35212377-542CC74E-FCC4-4FBD-8F4A-6F4C5801C40F

Q35212377-557D668A-80C9-4C3D-ACD5-B61CE64F10BA

Q35212377-83E551F7-3FBA-44A2-9EC2-4002D5D04215

Q35212377-8AB06F51-7DCF-4072-B371-7AAE86D17111

Q35212377-8C257B5E-C086-4BCB-9B8E-5E549B517EE7

Q35212377-8D0FE500-2F98-4A7E-8006-C18899E475B9

P304

Q35212377-F77AC515-7FB8-4138-BDE2-2D3F6CFC66C4

P31

Q35212377-584C3EAF-C1DA-48E8-8C92-006124675949

P356

Q35212377-574BCBE6-2E70-41C4-B0D0-8534D772B92D

P407

Q35212377-53991559-DAF0-4E48-9E53-52EF5B63BDF8

P433

Q35212377-66AB02AA-08AA-4B94-AFA7-6BF7F5A2F08A

P478

Q35212377-191834EF-F0C6-48DD-A4B4-9D6FCF0EFE78

P577

Q35212377-D5F7A30A-9362-49DE-94C9-9FAE8396E9B0

P5875

Q35212377-CCFDC5C8-924B-45BE-9389-1F443B0D015C

P698

Q35212377-74B905FE-C3B5-4859-A071-D7DF0D3F22DF

P921

Q35212377-4F1BFD85-C7A4-4C84-B086-FF9C9EBD903D

P932

Q35212377-F1886D41-AACF-469D-A6CF-FE7156F2AEE2

P356

BLOOD-2011-04-349134

P1433

P1476

Monoclonal and polyclonal seru ...... chronic lymphocytic leukemia.

@en

P2093

Brian K Link

http://www.w3.org/2001/XMLSchema#string

Clive S Zent

http://www.w3.org/2001/XMLSchema#string

Cristine Allmer

http://www.w3.org/2001/XMLSchema#string

Curtis A Hanson

http://www.w3.org/2001/XMLSchema#string

James R Cerhan

http://www.w3.org/2001/XMLSchema#string

Jerry A Katzmann

http://www.w3.org/2001/XMLSchema#string

Kari G Rabe

http://www.w3.org/2001/XMLSchema#string

Matthew J Maurer

http://www.w3.org/2001/XMLSchema#string

Neil E Kay

http://www.w3.org/2001/XMLSchema#string

Susan L Slager

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Immunoglobulin free light chains and solitary plasmacytoma of bone

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.

P304

2821-2826

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-04-349134

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51498298

http://www.w3.org/2001/XMLSchema#string

P698

21765023

http://www.w3.org/2001/XMLSchema#string

P921

P932

3172798

http://www.w3.org/2001/XMLSchema#string